Dr Reddy’s Laboratories gets a USFDA nod on Lenalidomide tablets

Dr Reddy’s Laboratories gets a USFDA nod on Lenalidomide tablets

by admin- Tuesday, October 19th, 2021 04:32:25 PM

Dr. Reddy’s Laboratories announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.Five mg and 20 mg strengths, and tentative popularity of five mg, 10 mg, 15 mg, and 25 mg strengths, a healing equivalent frequent model of REVLIMID (lenalidomide) Capsules, from america Food and Drug Administration (USFDA).

With this approval, Dr. Reddy’s is eligible for one hundred eighty days of common drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.

News Updates